![](https://endpts.com/wp-content/uploads/2019/04/nick-leschly-tile-2-credit-International-Society-for-Pharmaceutical-Engineering-ISPE.jpg)
EU stamps historic OK on bluebird’s gene therapy for β-thalassemia — now sit back and wait for the price
It’s official: bluebird bio has scored its first drug approval with an EU marketing authorization for its gene therapy for transfusion-dependent β-thalassemia.
Zynteglo is the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.